Prosecution Insights
Last updated: April 19, 2026
Application No. 18/270,291

RADIATION-CURABLE SILICONE COMPOSITION COMPRISING A RELEASE CONTROL ADDITIVE

Non-Final OA §103
Filed
Jun 29, 2023
Examiner
NELSON, MICHAEL B
Art Unit
1787
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Elkem Silicones France SAS
OA Round
2 (Non-Final)
21%
Grant Probability
At Risk
2-3
OA Rounds
4y 1m
To Grant
58%
With Interview

Examiner Intelligence

Grants only 21% of cases
21%
Career Allow Rate
114 granted / 537 resolved
-43.8% vs TC avg
Strong +37% interview lift
Without
With
+36.7%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
85 currently pending
Career history
622
Total Applications
across all art units

Statute-Specific Performance

§103
57.4%
+17.4% vs TC avg
§102
3.7%
-36.3% vs TC avg
§112
32.6%
-7.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 537 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claims 1-14 are pending. Applicant’s previous election of group I, claims 1-9, still applies and claims 10-14 are withdrawn. Response to Amendment Applicant’s amendment of 01/15/26 has been entered. The remarks regarding the rejection based on Allen as a primary reference are persuasive and this rejection is withdrawn. However, a new rejection is presented below. This action is accordingly non-final. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. If this application currently names joint inventors: in considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. When something is indicated as being “obvious” this should be taken as shorthand for “prima facie obvious to one having ordinary skill in the art to which the claimed invention pertains before the effective filing date of the invention”. When a range is indicated as overlapping a claimed range, unless otherwise noted, this should be taken as short hand to indicate that the claimed range is obvious in view of the overlapping range in the prior art as set forth in MPEP 2144.05, in the case where the claimed range “overlap or lie inside ranges disclosed by the prior art”, a prima facie case of obviousness exists, In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990). Claim(s) 1-9 is/are rejected under 35 U.S.C. 103 as being unpatentable over Dohler et al. (U.S. 6,268,404) in view of Allen (U.S. 2003/0064232) in view of Sherman (U.S. 2007/0148475). Regarding claims 1-9, Dohler teaches coating having adhesion and release properties (see object of the invention) that comprises a mixture of acrylate functional polysiloxanes, each of which overlaps the scope of claim 1 and has an overlapping concentration of acrylate groups as in claims 3-4 (discussed below), which may be free-radical cured via photons and a photoinitiator as in claim 2 (col. 4, lines 45-65), and may have additional organic acrylate compounds as in claim 9 (see claim 12, organic because acrylate groups are organic). The formula I and II compounds overlap the claimed formula and have overlapping ranges of acrylate content: for formula I, if R1 and R3 are methyl, and R2 is a (CH2)3OCOCHCH2 acrylate group, there may be zero a groups and 25 b groups yielding a acrylate concentration of over 500 mmol acrylate/100g polymer, or there may be 300 a groups (each having a MW of about 74) and 1 b group (having a MW of about 172) yielding a acrylate concentration of about 4 mmol/100 g polymer; for formula II, if R1 is methyl and R2 is a (CH2)3OCOCHCH2 acrylate group, there may be 5 c groups, yielding an acrylate concentration of over 300 mmol/100 g polymer, or there may be 500 c groups, yielding an acrylate concentration of about 5 mmol/100 g polymer (col. 3 line 1-col. 4, line 45). Thus, each of the two formula overlaps the acrylate concentrations of claims 3 and 4, and each may be the claimed A1 and A2 organopolysiloxane, with the ratio of the two formula (10:90-90:10) resulting in an amount of A2 that overlaps claim 5 (after accounting for the other ingredients in the composition). Dohler does not disclose the claimed OH siloxane additive (though additives/fillers are generally suggested, col. 4, lines 45-60). However, Allen is also directed to an acrylate functional polysiloxane composition having adhesion and release properties (i.e., pressure sensitive adhesive, [0109]) and teaches that hydroxy functional MQ resin, as in claim 8 may be included as a reinforcing agent, at an amount overlapping claim 6, with the silanol functionality also providing tackiness (a benefit to Dohler given the desired adhesion properties), (see abstract, [0068]-[0096]), such that it would have been obvious to have included such an MQ resin from Allen in Dohler to provide reinforcing effect and to have adjusted the OH content in such MQ resin to values within the range of claim 7 because Allen recognized the OH content as contributing to tackiness. In addition to the amount of OH MQ resin being overlapped as explained above, it is also a result effective variable that would have been obvious to optimize to within the claimed range as part of adjusting the amount of reinforcement/tackiness provided to the composition. Allen also discloses more details regarding the benefits of additional acrylate compounds (i.e., co-curing/crosslinkers, [0090]), as already generally suggested in Dohler, such that Allen provides additional obvious motivation for including the more particular acrylate compounds from Allen, as in claim 9, in Dohler to improve crosslinking (even though the general additional acrylate compounds from claim 12 of Dohler is already sufficient to render obvious claim 9). Regarding the OH concentration of claim 7, as explained above, Allen in modified Dohler already renders obvious optimization of such a range as a result effective variable in order to control tackiness, but Sherman makes the range of claim 7 further obvious because Sherman is also directed to OH functional MQ resins added for tackiness to a pressure sensitive adhesive (an adhesive with release properties) and teaches that suitable OH concentrations to achieve these effects overlaps claim 7 such that it would have been obvious to have used such an OH concentration for the OH functional MQ resin of modified Dohler because Sherman indicates it provides the sought after tackiness property (see abstract, [0011], [0079]-[0084]). Response to Arguments Applicant’s arguments are moot because of the new ground of rejection. Applicant notes that claim 14 was inadvertently omitted from the withdrawn claims, even though only claims 1-9 were elected. The examiner confirms that Applicant is correct in determining that claim 14 is also withdrawn. Applicant also asks that the previous restriction requirement be withdrawn for the same reasons that the previous rejection in the last office action was withdrawn. However, as indicated above, claim 1 still fails to make a contribution over the art in view of the new rejection above and thus the restriction requirement is maintained. It is noted that while Applicant’s remarks are persuasive against Allen as a primary reference, the reference is still applicable as a secondary reference. The high MW silicone in Allen does not affect the teachings regarding the MQ resin, which is obvious to include in Dohler as explained above. Furthermore, while Applicant indicates that Dohler does not report acrylate concentrations in mmol/100g, this is not necessary and the scope of the respective formula in Dohler results in an acrylate concentration that overlaps all the claimed ranges. Conclusion References cited in any corresponding foreign applications have been considered but would be cumulative to the above. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL B NELSON whose direct telephone number is (571)272-9886 and whose direct fax number is (571)273-9886 and whose email address is Michael.Nelson@USPTO.GOV. The examiner can normally be reached on Mon-Sat, 7am - 7pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Callie Shosho can be reached on 571-272-1123. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300 (faxes sent to this number will take longer to reach the examiner than faxes sent to the direct fax number above). Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL B NELSON/ Primary Examiner, Art Unit 1787
Read full office action

Prosecution Timeline

Jun 29, 2023
Application Filed
Oct 14, 2025
Examiner Interview (Telephonic)
Oct 15, 2025
Non-Final Rejection — §103
Jan 15, 2026
Response Filed
Jan 31, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12576187
ANTIADHESIVE SUPERHYDROPHOBIC SURFACES
2y 5m to grant Granted Mar 17, 2026
Patent 12545803
COATING AGENT, RESIN MEMBER, AND PRODUCTION METHOD THEREFOR
2y 5m to grant Granted Feb 10, 2026
Patent 12545804
BIOCIDAL POLYMER FOR LONG-TERM SURFACE PROTECTION
2y 5m to grant Granted Feb 10, 2026
Patent 12540216
TWO-COMPONENT MOISTURE CURABLE THERMAL INTERFACE MATERIAL FOR THERMAL MANAGEMENT SYSTEMS
2y 5m to grant Granted Feb 03, 2026
Patent 12534650
COMPOSITION FOR PREPARING A RELEASE COATING AND METHOD OF PREPARING COATED SUBSTRATE
2y 5m to grant Granted Jan 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

2-3
Expected OA Rounds
21%
Grant Probability
58%
With Interview (+36.7%)
4y 1m
Median Time to Grant
Moderate
PTA Risk
Based on 537 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month